1-3 of 3
Nancy Havrilla
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease

Clinical Trials & Observations
Margaret L. MacMillan, Daniel Couriel, Daniel J. Weisdorf, Gisela Schwab, Nancy Havrilla, Thomas R. Fleming, Saling Huang, Lorin Roskos, Shimon Slavin, Richard K. Shadduck, John DiPersio, Mary Territo, Steve Pavletic, Charles Linker, Helen E. Heslop, H. Joachim Deeg, Bruce R. Blazar
Journal: Blood
Blood (2006) 109 (6): 2657–2662.
https://doi.org/10.1182/blood-2006-08-013995
Published: 2006
Journal Articles

A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agent SNS-595 in Advanced Leukemias.

Jeffrey E. Lancet, MD, Judith E. Karp, MD, Nancy Havrilla, Ute Hoch, PhD, Jeffrey Silverman, PhD, Daniel Adelman, MD, Francis J. Giles, MD
Journal: Blood
Blood (2006) 108 (11): 1962.
https://doi.org/10.1182/blood.V108.11.1962.1962
Published: 2006
Journal Articles

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL

Clinical Trials & Observations
H. Joachim Deeg, Bruce R. Blazar, Brian J. Bolwell, Gwynn D. Long, Friedrich Schuening, John Cunningham, Robert M. Rifkin, Sunil Abhyankar, Adrienne D. Briggs, Richard Burt, John Lipani, Lorin K. Roskos, J. Michael White, Nancy Havrilla, Gisela Schwab, Helen E. Heslop
Journal: Blood
Blood (2001) 98 (7): 2052–2058.
https://doi.org/10.1182/blood.V98.7.2052
Published: 2001